Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy with

sunitinib
metastasis
interleukin-2
pembrolizumab
liver metastasis
  • 319 views
  • 24 Oct, 2022
  • 349 locations
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer (CONTACT-02)

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second

metastasis
abiraterone
progressive disease
metastatic castration-resistant prostate cancer
adenocarcinoma
  • 0 views
  • 21 Oct, 2022
  • 254 locations
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) (LIBRETTO-531)

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants …

metastasis
cancer
progressive disease
measurable disease
renal function
  • 31 views
  • 20 Oct, 2022
  • 152 locations
Cabozantinib in Advanced Adrenocortical Carcinoma (CaboACC)

)further lines of therapy, single agent treatment with cabozantinib off label resulted in three partial responses and five additional cases of disease stabilization for four months or longer (Kroiss et al

cancer
measurable disease
etoposide
streptozotocin
c-MET
  • 3 views
  • 04 Oct, 2022
  • 1 location
Cabozantinib and Nivolumab for Carcinoid Tumors

This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another term used to refer to

neuroendocrine tumor
metastasis
line of therapy
spiral computed tomography
carcinoid tumor
  • 0 views
  • 24 Mar, 2022
  • 1 location
Cabozantinib and Pembrolizumab in Metastatic Pancreas

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

breast ductal carcinoma
tyrosine
pancreatic adenocarcinoma
adenocarcinoma
pancreatic ductal adenocarcinoma
  • 0 views
  • 14 Mar, 2022
  • 1 location
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as

liver transplant
hepatocellular carcinoma
cancer
tyrosine
liver cancer
  • 0 views
  • 18 Apr, 2021
  • 1 location
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB)

Cabozantinib (also known as Cabometyx). This drug has been used previously in many cancers, including clear cell kidney cancer and thyroid cancer. The purpose of this study is to test the effectiveness

metastasis
renal function
liver metastasis
curative surgery
serum pregnancy test
  • 37 views
  • 24 Mar, 2022
  • 11 locations
Cabozantinib for Patients With Recurrent or Progressive Meningioma

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

karnofsky performance status
renal function
platelet count
hysterectomy
measurable disease
  • 0 views
  • 08 Jul, 2022
  • 1 location
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung

HIV Infection
metastasis
bevacizumab
hepatitis b
monoclonal antibodies
  • 25 views
  • 20 Oct, 2022
  • 437 locations